Zosuquidar

DB06191InvestigationalSmall molecule

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the... Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

Chemical structure of Zosuquidar
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in leukemia (myeloid) and myelodysplastic syndrome.Curator reviewed
Formula / weight
C32H31F2N3O2 · 527.616 g/mol (avg)

Resolves to

Structure
InChIKeyIHOVFYSQUDPMCN-DBEBIPAYSA-NSMILES[H][C@]12C3=CC=CC=C3[C@H](N3CCN(C[C@@H](O)COC4=CC=CC5=C4C=CC=N5)CC3)C3=CC=CC=C3[C@@]1([H])C2(F)F

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
164Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Zosuquidar, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account